about
Protective effect of bisphosphonates on endometrial cancer incidence in data from the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial.The biological basis for modern treatment of chordoma.Effects of glucosamine and risedronate alone or in combination in an experimental rabbit model of osteoarthritis.Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck.The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases.Potential pathophysiological mechanisms in osteonecrosis of the jaw.In vivo effects of zoledronic acid on oral mucosal epithelial cellsMatrix metalloproteinases in cancer: prognostic markers and therapeutic targets.Bisphosphonates and periodontics: potential applications for regulation of bone mass in the periodontium and other therapeutic/diagnostic uses.Role of matrix metalloproteinases and therapeutic benefits of their inhibition in spinal cord injury.Liposome encapsulated zoledronate favours M1-like behaviour in murine macrophages cultured with soluble factors from breast cancer cells.Comparison of various SYSADOA for the osteoarthritis treatment: an experimental study in rabbits.Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease.Adjuvant pamidronate therapy prevents the development of bone metastases in breast cancer patients with four or more positive nodes.Biphosphonates in advanced prostate and renal cell cancer--current status and potential applications.Zoledronic acid reverses the epithelial-mesenchymal transition and inhibits self-renewal of breast cancer cells through inactivation of NF-κBPamidronate Down-regulates Tumor Necrosis Factor-alpha Induced Matrix Metalloproteinases Expression in Human Intervertebral Disc Cells.Expression analysis of matrix metalloproteinase-9 in epithelialized and nonepithelialized apical periodontitis lesions.Pharmacokinetic profile of bisphosphonates in the treatment of metabolic bone disorders.An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis.Atrial fibrillation and bisphosphonate therapy.Matrix metalloproteinase-2 as a target for head and neck cancer therapy.Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment.Effects of intra-articular clodronate in the treatment of knee osteoarthritis: results of a double-blind, randomized placebo-controlled trial.Prostate cancer presenting with normal serum PSA levels and boney metastases treated with zoledronic acid.Matrix metalloproteinases, tissue inhibitor of matrix metalloproteinase-1, and laminin-5 gamma2 chain immunolocalization in gingival tissue of endotoxin-induced periodontitis in rats: effects of low-dose doxycycline and alendronate.The effects of MMP inhibitors on human salivary MMP activity and caries progression in rats.Effects of low-dose, noncytotoxic, intraarticular liposomal clodronate on development of erosions and proteoglycan loss in established antigen-induced arthritis in rabbits.A combination of a chemically modified doxycycline and a bisphosphonate synergistically inhibits endotoxin-induced periodontal breakdown in rats.Recovery of bone mass and normalization of bone turnover in long-term survivors of allogeneic bone marrow transplantation.Combined local application of tetracycline and bisphosphonate reduces alveolar bone resorption in rats.A histopathological investigation on the effect of systemic administration of the bisphosphonate alendronate on resorptive phase following mucoperiosteal flap surgery in the rat mandible.Bisphosphonates, atherosclerosis and vascular calcification: update and systematic review of clinical studies.Effects of combined systemic administration of low-dose doxycycline and alendronate on endotoxin-induced periodontitis in rats.Osteomylelitis and necrosis of the jaw in patients treated with bisphosphonates: a comparative study focused on multiple myeloma.Potential implications of matrix metalloproteinase-9 in assessment and treatment of coronary artery disease.1% alendronate gel as local drug delivery in the treatment of Class II furcation defects: a randomized controlled clinical trial.Inhibition of osteoclast differentiation and matrix metalloproteinase production by CD4+CD25+ T cells in mice.Effects of alendronate and hormone replacement therapy, alone and in combination, on saliva, periodontal conditions and gingival crevicular fluid matrix metalloproteinase-8 levels in women with osteoporosis.Circulating matrix metalloproteinase-9 and osteoporosis in patients with chronic obstructive pulmonary disease.
P2860
Q30881569-F82CBE6D-87AC-4317-96EF-BCA1C604E0F8Q33274086-0744D765-EA53-4E56-BBA2-819E4A3CD8D3Q33622130-541C8852-10F2-4E74-9BA3-E74C5EC2CA7EQ33758871-6A184E94-BDB5-4012-8711-53DE74999940Q33970557-15E82587-CEA8-4F79-A513-56A9B3460681Q34162359-CDE6C03D-B3F5-485B-98B1-09BAD46D30C0Q34441640-05D538DF-C246-4006-AD7C-008A230CB6CEQ34616803-77B2A3E8-0A6C-4E6F-BCE2-D99DB1DECEC2Q34765492-5A291CC1-E69A-4140-82BE-6EBE906AC001Q34801330-6ADE0AD0-9C04-46D4-9299-92F60870330EQ35008733-1E4E0E9F-A4B5-4345-909D-27FFF95439FAQ35634428-8B5981A7-9083-4A15-93AC-18DB4600CCEBQ35987738-D4CE8B7B-60EB-46FE-B066-824BA027019BQ36216730-DC44657C-2F12-4274-B0D6-277AAC776B17Q36403183-1957BFD5-03A7-440C-B913-1623F5A75BEEQ37012308-B293FE42-A2A1-4251-B867-4CA7CF89EE6EQ37247142-1D500CA9-897A-46C5-9911-B01A7474EDCEQ37342733-3E1E8531-9F27-47A0-9BFE-32C300F19C29Q37430269-121EB2FA-A25E-4916-AA00-E15B6CD983FAQ37486791-EAFF993A-C3E6-46C7-8AEB-6A7D392C2BFFQ37679127-113C98D2-CD34-4928-81D3-F095A7802452Q38068476-5A8EA1E3-FA02-4D4A-9C99-709601A46A92Q38725320-364A75E5-474D-4E58-8482-A293EC40A84AQ39203039-3488E27C-642A-4B78-B110-3A3B923E5CC5Q39360745-E1A98DC9-9C7C-43D5-97F3-D9EA3937E742Q42506243-AC81801F-A1DE-478F-B7EF-724784DE9014Q43703465-58D1ABB6-B8CE-417A-B314-D050413362D3Q43709169-38B61044-2F52-4894-8408-3EA16C0E7804Q43721782-0995495E-B3AE-4E27-8E46-816611311E4FQ43882646-99CBABEE-F2A7-4F4E-9BE1-E4B3C47A0703Q44558092-B1FD83A2-EB66-419F-A45D-865A9FA2D9F3Q44636319-EF4CF276-A61C-48CF-8BB4-E26FC3E863BBQ44657342-66C32ACA-F35D-4BAF-89BA-BEB718347C8BQ45212365-2ADDC37F-7E34-47C7-9F56-3C214B523BFAQ45257401-4282E2BF-1A28-41CF-B7AB-023061733AF0Q46069799-8F6ACCE2-34CC-4C3B-B0AC-3F781939B1A1Q46106011-C5405446-0249-4AFA-A831-C1DF608C2228Q46610991-698FD384-B0AF-4CA0-B589-4CE10D6C9B27Q46942434-F5431D2C-302E-4182-AB23-AD7B39A2B9EDQ47893382-6DC641DD-0192-48ED-A48D-03D2DFBF742C
P2860
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
MMP inhibition and downregulation by bisphosphonates.
@en
type
label
MMP inhibition and downregulation by bisphosphonates.
@en
prefLabel
MMP inhibition and downregulation by bisphosphonates.
@en
P2093
P2860
P1476
MMP inhibition and downregulation by bisphosphonates
@en
P2093
P Heikkilä
R Hanemaaijer
Y T Konttinen
P2860
P304
P356
10.1111/J.1749-6632.1999.TB07702.X
P407
P577
1999-06-01T00:00:00Z